50 results
Page 2 of 3
6-K
EX-99.3
puokd88xq6p8l
5 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.1
mzz7k29n
26 Jul 22
InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients
8:35am
6-K
EX-99.3
h3ebas
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.1
atd3 r89ngs64
7 Apr 22
Current report (foreign)
4:01pm
6-K
EX-99.1
ixpt7sz x9vd7mt8hveu
31 Mar 22
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients
4:51pm
6-K
EX-99.1
0w7mq
1 Mar 21
Current report (foreign)
12:00am
6-K
EX-5.2
eqx 4a9rx6ys3alb
1 Mar 21
Current report (foreign)
12:00am
424B5
s42ymu65dv y6
26 Feb 21
Prospectus supplement for primary offering
5:10pm
424B5
a1ln rkkmbov63xuf
24 Feb 21
Prospectus supplement for primary offering
5:16pm
6-K
gnnn51 ueuyg
24 Feb 21
Current report (foreign)
4:16pm
424B5
s41f45pb
20 Jul 20
Prospectus supplement for primary offering
9:21am
6-K
EX-99.1
hgfa75y1mpylkq6ty2
20 Jul 20
from 6-K
9:02am
F-3
3gk7ybkxx
8 Jul 20
Shelf registration (foreign)
12:00am
F-3
EX-5.2
ffx88s
8 Jul 20
Shelf registration (foreign)
12:00am
6-K
bgwy bee466
2 Mar 20
Current report (foreign)
4:05pm